tDCS for Schizophrenia and Schizoaffective Disorder
Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia
Recruiting
Observational Study
SchizophreniaSchizoaffective
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
20 (estimated)
Sponsor
Centre for Addiction and Mental Health · Other
Who this trial is looking for
This trial is looking for patients with schizophrenia or schizoaffective disorder to study brain changes using a technique called tDCS. Participants will need to already be involved in a related study and meet certain health criteria.
Are You a Good Fit for This Trial?
Rules you outSevere thought disorderRecent substance dependence
You may be able to join if
I am at least 18 years old
I have been diagnosed with schizophrenia or schizoaffective disorder
I can consent to participate in this study
I have been on stable oral antipsychotic medication for at least 2 months
You may not be able to join if
I am unable to consent to the study
I have unstable medical or neurological illnesses
I have acute suicidal or homicidal thoughts
I have serious thought disturbances
I have a recent substance dependence issue
I have a positive drug test result
I have metal implants or a pacemaker
I am pregnant
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This study will examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia. Synaptic density levels will be measured using a novel positron emission tomography (PET) radiotracer \[18F\]SDM-8, which is currently the best-in-class method to quantify synaptic density in humans. This will be a companion study to a parent study b…
This study will examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia. Synaptic density levels will be measured using a novel positron emission tomography (PET) radiotracer \[18F\]SDM-8, which is currently the best-in-class method to quantify synaptic density in humans. This will be a companion study to a parent study by our group examining the effects of tDCS on treatment adherence in schizophrenia (REB #103-2018).
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
Enrolment in the tDCS-adherence parent study (REB# 103-2018). The parent study inclusion criteria are:
1. Male or female participants of any race or ethnicity
2. Inpatients or outpatients ≥18 years of age
3. DSM-V diagnosis of schizophrenia or schizoaffective disorder
4. Capabl…
Inclusion Criteria:
Enrolment in the tDCS-adherence parent study (REB# 103-2018). The parent study inclusion criteria are:
1. Male or female participants of any race or ethnicity
2. Inpatients or outpatients ≥18 years of age
3. DSM-V diagnosis of schizophrenia or schizoaffective disorder
4. Capable of consenting to participate in the research study
5. On a stable dose of oral antipsychotic drug and other concomitant medications for at least 2 months, and unlikely to undergo changes in dose during the study.
Exclusion Criteria:
The exclusion criteria for this study will be the same as the parent study (REB 103-2018). The parent study exclusion criteria are:
1. Unwilling or incapable to consent to the study based on the MacArthur Test of Competence
2. Unstable medical or any concomitant major medical or neurological illness, including a history of seizures
3. Acute suicidal or homicidal ideation
4. Formal thought disorder rating ≥3 on the Positive and Negative Syndrome Scale (PANSS) P2 conceptual disorganization item
5. DSM-V substance dependence (except caffeine, nicotine, and cannabis/marijuana) within 1 month of entering the study
6. Positive urine drug screen except for cannabis/marijuana at the screening visit
7. Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (e.g., claustrophobia)
8. Pregnancy
9. Score \<32 on the Wide Range Achievement Test-III
Additional exclusion criteria for this companion study are:
1. Unwilling or incapable to consent to the study based on the MacArthur Test of Competence
2. Exposure to long-acting injectable antipsychotics in the last 6 months
3. Exceeding allowed annual radiation exposure levels (20 mSv), as outlined by our PET Centre guidelines
4. Receiving treatment with medications such as levetiracetam that blocks SV2a binding
5. Disorders of coagulation or taking anticoagulant medication
6. Having completed multiple PET scans in the past, such that participation in this study would cause participant to exceed lifetime limit (8 PET scans)
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.